FLX-925
- Generic Name
- FLX-925
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02335814
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath